Previous Close | 50.22 |
1-Year Change | 58.52% |
6-Months Change | -15.64% |
3-Months Change | -11.05% |
Moving Avg (50d) | 54.08 |
Moving Avg (200d) | 60.126 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 4.82M |
Beta (3-Years) | 1.12 |
Revenue Growth (ttm) | -94.73% |
Net Profit Margin (ttm) | -6739.96% |
Return On Assets (ttm) | -71.12% |
EPS (ttm) | -5599.57 |
PE Ratio (ttm) | -0.01 |
Dividend Yield | % |
Asset Description: | Cytokinetics, Incorporated |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-12 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
50.082 | 51.555 | 52.537 | 54.01 | 56.465 | 58.92 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.